Literature DB >> 15342219

S-cone, L + M-cone, and pattern, electroretinograms in ocular hypertension and glaucoma.

Yousef H Aldebasi1, Neville Drasdo, James E Morgan, Rachel V North.   

Abstract

Silent substitution and selective adaptation techniques were used to obtain full field S-cone and L + M-cone electroretinograms from 18 patients with ocular hypertension (OHT), 9 with normotensive glaucoma (NTG), 18 with early primary open angle glaucoma (POAG) and 19 normal controls. Pattern electroretinograms were also recorded, using a reduced check size to increase the contribution of retinal ganglion cells. In the OHT and POAG groups, statistically significant reductions (P = 0.05-0.001) were observed in the amplitudes, most notably in the late negative waves of all three types of ERG compared to the controls. These are thought to reflect ganglion cell activity. The results imply a diffusely distributed loss of activity (20-35%) affecting many retinal pathways to a similar extent in OHT and early POAG, with an additional amount (<5%) in POAG corresponding approximately to the loss associated with local field defects. The electrophysiology indicated that virtually all cases of untreated OHT have greater retinal dysfunction than the least affected cases of POAG. The NTG group showed a different pattern of loss in that the PERG was markedly affected but the S-cone ERG was not significantly reduced.

Entities:  

Mesh:

Year:  2004        PMID: 15342219     DOI: 10.1016/j.visres.2004.06.015

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  16 in total

1.  Head-down posture induces PERG alterations in early glaucoma.

Authors:  Lori M Ventura; Iuri Golubev; William Lee; Izuru Nose; Jean-Marie Parel; William J Feuer; Vittorio Porciatti
Journal:  J Glaucoma       Date:  2013-03       Impact factor: 2.503

2.  Retinal pathway origins of the pattern electroretinogram (PERG).

Authors:  Xunda Luo; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-01       Impact factor: 4.799

3.  The effect of broadband and monochromatic stimuli on the photopic negative response of the electroretinogram in normal subjects and in open-angle glaucoma patients.

Authors:  Maja Sustar; Barbara Cvenkel; Jelka Brecelj
Journal:  Doc Ophthalmol       Date:  2008-10-19       Impact factor: 2.379

4.  Electoretinographic evidence of retinal ganglion cell-dependent function in schizophrenia.

Authors:  Pantea Moghimi; Nathalia Torres Jimenez; Linda K McLoon; Theoden I Netoff; Michael S Lee; Angus MacDonald; Robert F Miller
Journal:  Schizophr Res       Date:  2019-10-12       Impact factor: 4.939

5.  MfERG responses to long-duration white stimuli in glaucoma patients.

Authors:  Margarita G Todorova; Anja M Palmowski-Wolfe
Journal:  Doc Ophthalmol       Date:  2011-02-22       Impact factor: 2.379

6.  TRP channel gene expression in the mouse retina.

Authors:  Jared C Gilliam; Theodore G Wensel
Journal:  Vision Res       Date:  2011-10-20       Impact factor: 1.886

7.  Pattern electroretinogram and glaucoma.

Authors:  G van Lith; P Ringens; L J de Heer
Journal:  Dev Ophthalmol       Date:  1984

8.  Structure-function relationship in ocular hypertension and glaucoma: interindividual and interocular analysis by OCT and pattern ERG.

Authors:  Benedetto Falsini; Dario Marangoni; Tommaso Salgarello; Giovanna Stifano; Lucrezia Montrone; Francesca Campagna; Stefania Aliberti; Emilio Balestrazzi; Alberto Colotto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

9.  Pattern ERG and RNFL thickness in hypertensive eyes with normal blue-yellow visual field.

Authors:  Maurizio G Uva; Massimo Di Pietro; Antonio Longo; Katia Lauretta; Michele Reibaldi; Alfredo Reibaldi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-12       Impact factor: 3.117

Review 10.  Pattern electroretinogram in glaucoma.

Authors:  Lori M Ventura; Vittorio Porciatti
Journal:  Curr Opin Ophthalmol       Date:  2006-04       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.